Adjunctive everolimus therapy in tuberous sclerosis-associated refractory epilepsy
journal contributionposted on 20.04.2021, 16:48 by S Al Hatmi, A Breen, H El Naggar, M Morrin, Norman DelantyNorman Delanty
Presentation In this article we are reporting the beneficial impact of everolimus treatment on the renal & CNS manifestations of TSC.
Diagnosis The patient diagnosed with refractory seizure associated with tuberous sclerosis.
Treatment The patient was treated with everolimus, and he was commenced at a dose of 10 mg daily.
Conclusion This report shows that everolimus treatment for three years of refractory seizures in patients with TSC, can lead to a clinically meaningful reduction in seizure frequency. Compared with other anti-epileptic medications, everolimus demonstrated additional benefits in reducing Subependymal giant cell astrocytoma (SEGA) and renal angiomyolipoma volume. At the time of preparation of this report, the patient continue treatment with daily everolimus without adverse events.
CommentsThe original article is available at imj.ie
Published CitationAl Hatmi S, Breen A, El Naggar H, Morrin M, Delanty N. Adjunctive everolimus therapy in tuberous sclerosis-associated refractory epilepsy. Irish Medical Journal. 2020;113(10):218
Publication DateDecember 2020
- Beaumont Hospital
- FutureNeuro Centre
PublisherIrish Medical Association
- Published Version (Version of Record)